Table 1.

Comparison of immune responses to PCV10 versus PCV7 among infants

Study	Vesikari et al. [38]								Kim et al. [39]
Country (year)	Finland, France and Poland (2009)								Korea (2011)
Dosing schedule	3 doses (2, 3, 4 months)								3 doses (2, 4, 6 months)
Vaccine	PCV7				PCV10				PCV7				PCV10
Immunogenicity	OPA titer		ELISA(IgG, μg/mL)		OPA titer		ELISA(IgG, μg/mL)		OPA titer		ELISA(IgG, μg/mL)		OPA titer		ELISA(IgG, μg/mL)
	GMT	≥1:8 (%)	GMC	≥0.20 (%)	GMT	≥1:8 (%)	GMC	≥0.20 (%)	GMT	≥1:8 (%)	GMC	≥0.20 (%)	GMT	≥1:8 (%)	GMC	≥0.20 (%)
PCV7 serotypes
4	1,010	100	2.78	100	735	99.6	1.45	97.1	1,457	100	5.35	100	632	98.1	4.00	99.7
6B	999	95.5	0.59	79.0	457	92.4	0.33	65.9	1,456	100	2.07	98.4	597	93.8	1.40	92.4
9V	1,233	100	2.68	99.5	1,400	100	1.32	98.1	1,901	98.4	5.09	99.2	1,051	99.4	3.39	99.7
14	1,891	98.9	4.49	99.5	1,061	99.6	2.90	99.5	2,169	98.4	8.51	100	1,248	98.8	5.54	99.4
18C	212	95.5	2.46	98.9	130	93.6	1.66	96.0	389	96.8	5.13	100	157	89.3	5.80	99.7
19F	52	92.1	3.42	99.2	149	87.7	1.84	95.4	75	90.2	2.77	100	358	97.0	7.41	98.8
23F	4413	97.7	1.34	94.1	1,010	93.9	0.53	81.4	9,336	98.4	3.94	98.4	1,489	97.6	1.96	96.2
Other serotypes
1	5	4.5	0.03	4.0	25	65.7	1.05	97.3	6	12.9	0.04	5.7	188	92.6	3.41	100
5	5	3.4	0.03	1.9	60	90.9	1.70	99.0	5	9.7	0.07	14.6	238	97.6	4.52	100
7F	10	18.2	0.04	4.5	2254	99.6	1.72	99.5	152	67.8	0.03	3.3	3,968	100	4.08	100
Cross-reactive serotypes
6A	83	68.5	0.10	31.2	41	58.0	0.07	22.2	358	90.0	0.48	69.1	189	84.8	0.38	67.4
19A	5	3.4	0.11	28.7	9	19.6	0.08	22.6	5	11.7	0.12	26.8	11	32.7	0.29	59.0

OPA, opsonophagocytosis assay; GMC, geometric mean concentration; GMT, geometric mean titer (calculated from the reciprocal of the individual titers)